Testicular germ cell cancer (TGCC) is derived from germ cell neoplasia in situ (GCNIS), which arises due to niche disturbances affecting the Sertoli cells. It is believed that exogenous endocrine factors have a crucial role in governing neoplastic transformation but on a strong hereditary background. Follicle-stimulating hormone (FSH) is the major regulatory hormone of the Sertoli cells. FSH signalling-related single-nucleotide polymorphisms (SNPs) have previously been shown to affect FSH action in men at different levels. We aimed to investigate whether three FSH-related SNPs (FSHR 2039A>G, FSHR -29G>A and FSHB -211G>T) are associated with development of TGCC. A total of 752 Danish and German patients with TGCC from two tertiary andrological referral centres were included. Three control groups comprising 2020 men from the general population, 679 fertile men and 417 infertile men, were also included. Chi-squared test was performed to compare genotype-and allele frequencies. Kruskal-Wallis test was performed to compare age at diagnosis. Patients with TGCC had a higher frequency of the A-allele of FSHR 2039A>G compared to the group of fertile men with an AA-genotype frequency of 30.2% vs. 22.0%, respectively, p = 0.002. This variant is associated with higher FSH receptor activity. The distribution of the FSHR 2039A>G did not differ significantly between the patients with TGCC and the infertile or the general population. The frequency of the two other SNPs did not differ between patient with TGCC and any of the control groups. No differences were detected between genotypes and age distribution or histological subtype of the tumours. In conclusion, we observed that a genetic variant associated with FSHR activity may modulate the susceptibility to TGCC.
INTRODUCTION
Throughout the latest 30-40 years, there has been an increase in incidence of testicular germ cell cancer (TGCC) especially among Caucasian men and with the highest rates in Norway and Denmark (Purdue et al., 2005; Zengerling et al., 2014; Znaor et al., 2015) . Whilst it is suggested that the aetiology of TGCC is mainly environmental and affected by factors disrupting gonadal development during foetal life as recently reviewed (Rajpert-De Meyts et al., 2015; Skakkebaek et al., 2016) , TGCC is also among the cancer types most affected by genetic susceptibility (Stadler et al., 2010) . TGCC is derived from a pre-invasive germ cell neoplasia in situ (GCNIS), which most likely arise from transformed foetal germ cells that failed to differentiate due to niche disturbances affecting the Sertoli cells (Sonne et al., 2009) . It is assumed that all cases of GCNIS will progress into TGCC (Skakkebaek et al., 1981) . Follicle-stimulating hormone (FSH) is one of the major hormones responsible for stimulating Sertoli cell proliferation and maturation throughout life. It is therefore plausible that genetic variants modulating the FSH action could influence reproductive parameters (T€ uttelmann et al., 2012; Grigorova et al., 2014) including the susceptibility to TGCC. Three common single-nucleotide polymorphisms (SNPs), FSHB -211G>T (rs10835638), FSHR -29G>A (rs1394205) and FSHR 2039A>G (rs6166), have been shown in vitro to be associated with reduced FSHB promoter activity (Hoogendoorn et al., 2003) , reduced FSH receptor cell surface expression (Desai et al., 2011) and reduced FSH receptor signalling dynamics (Gromoll & Simoni, 2005; Casarini et al., 2014) , respectively. A preliminary study in an Italian population suggested an association between the FSHR 2039A>G and susceptibility to TGCC (Ferlin et al., 2008) , but this observation has not yet been repeated independently. To explore any possible association between these three SNPs and TGCC, we investigated the frequencies and distribution of the genetic variants alone and in combination in a binational collaborative study comprising two large groups of Danish and German TGCC cases and controls.
MATERIALS AND METHODS
All study subjects were retrospectively included from two tertiary andrological referral centres: The Department of Growth and Reproduction (GR), Copenhagen, Denmark, and the Centre of Reproductive Medicine and Andrology (CeRA), M€ unster, Germany. All were of Caucasian ethnicity and either of German or Danish origin.
Patients with TGCC
In total, information on 752 patients with TGCC was included; 527 Danish with a median age of 31 years (range: 16-53) at time of diagnosis and 225 German with a median age of 29 (range: 16-52) at time of diagnosis of TGCC. The men had been referred for cryopreservation of semen prior to treatment for TGCC (identified as an overt tumour), GCNIS and/or TGCC detected in connection with work-up for infertility or for treatment of suspected testosterone deficiency caused by previous TGCC.
Among the Danish patients, 449 had unilateral TGCC, 24 men had developed bilateral tumours, and 36 men were diagnosed with a unilateral tumour and contralateral GCNIS. Eighteen men did not have tumours, but were diagnosed with unilateral GCNIS (n = 14) or bilateral GCNIS (n = 4). Histology reports regarding TGCC types were available for 482 Danish patients (95% of the 509 with tumours) and 265 (55%) had been diagnosed with seminomas and 217 (45%) with non-seminomas. For the 225 German patients, histology reports were available for all and 104 (46%) had been diagnosed with seminomas and 121 (54%) with nonseminomas. Combined, 52.2% of the patients were affected by seminomas and 47.8% by non-seminomas. Results of contralateral biopsies were not available for the German men, but two men were diagnosed with bilateral tumour.
Although some of the patients were only affected by non-invasive GCNIS, to simplify the description, we will refer to the entire group as patients with TGCC.
Controls
Three groups of men served as control groups: men from the general population, men with proven fertility and men attending for male infertility.
Men from the general population
A total of 2020 men, median age 19 years (range 18-29) from the general Danish population who took part in an ongoing study on testicular function (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . They were included during a compulsory medical examination before their military service, as described in details previously (Jørgensen et al., 2012) . Men appearing before the draft board are considered representative of the general population of young, healthy men in Denmark. They were unselected by their fertility status but underwent a comprehensive andrological evaluation. The studied group had a median (5-95 th percentile) total sperm count of 143 million (14-534) and testis size (Prader orchidometer) of 21.0 ml (13.5-28.8).
Fertile men
Danish fertile controls consisted of 550 men, median age 31 years (range 22-46). The men were included during two periods (1996-1998 and 2012-2014) when they took part in a study of testicular function of fertile men as previously described (Jør-gensen et al., 2001) . The men were included when their female partners were pregnant. The pregnancies had been achieved by intercourse (i.e. not as a result of fertility treatment) within the recent 6 months prior to inclusion. Their median (5-95 th percentile) total sperm count was 232 million (34-785) and testis size (Prader orchidometer) 22.5 ml (13.5-30.0). German fertile controls consisted of 129 men, median age of 47 years (25-84) that had ever fathered a naturally conceived child.
Infertile men
In total, 417 Danish infertile men, median age 34 years (range 18-56), were also included as controls. The men had been referred for diagnostic work-up prior to treatment of their partner by either in vitro fertilization or intracytoplasmic sperm injection (2012) (2013) (2014) due to male infertility. Men with a past history of cryptorchidism, small surgery or infection of the genital tract were not excluded. The group of infertile men had a median (5-95 th percentile) total sperm count of 45 million (0.3-381) and testis size (Prader orchidometer) of 19 ml (10.0-26.5). For all three Danish control groups, we excluded men with azoospermia, use of anabolic steroids, chronic or newly diagnosed serious disease or serious testicular injury or surgery.
Genotyping
The Danish DNA samples were analysed as follows: peripheral blood (EDTA-preserved) was used for isolation of genomic DNA, and genotyping was performed with KASP ™ (LGC Genomics, Hoddesdon, UK) genotyping assays as described before (Busch et al., 2016) . DNA samples from 1073 men from the general population were analysed by LGC Genomics in Hoddesdon, UK, whereas all others were genotyped (with the same assays) at the Department of Growth and Reproduction. Only, the samples that clearly clustered to a specific genotype were included in the study. All samples within homozygous minor allele cluster were reanalysed, and in all cases, the initial results were verified. Samples representing each genotype (verified by Sanger sequencing) served as positive controls and omission of DNA as negative controls. The German DNA samples were analysed at the Centre of Reproductive Medicine and Andrology as follows: genomic DNA was extracted from EDTA-preserved blood using the FlexiGene DNA extraction kit (QIAGEN, D€ usseldorf, Germany) or the DNA Extract All Kit (Applied Biosystem, Darmstadt, Germany). Rs10835638, rs1394205 and rs6166 were analysed by PCR and allelic discrimination assay on the ABIPRISM7000 or the StepOnePlus detection system (Applied Biosystems, Darmstadt, Germany). The TaqMan GTXpressMaster Mix and TaqMan SNP Genotyping Assays customized for the SNPs were used (Applied Biosystems, Darmstadt, Germany). As internal controls, DNA samples with homozygous genotypes for each variant were included in every run.
Statistical analysis
Differences in genotype and allele distributions between patients and control groups as well as subgroups were compared by chi-squared test. Difference in age at diagnosis between genotypes was tested by Kruskal-Wallis test. Odds ratio was calculated for significant findings. In addition, a meta-analysis, separately including both the Danish and the German cases and fertile controls (German patients with TGCC vs. German fertile controls and Danish patients with TGCC vs. Danish fertile controls), was performed with the 'meta' package (http://cran.r-pro ject.org/webpackages/meta/index.html) for the statistical package R (http://www.r-project.org) using inverse variance method under the fixed-effects model. Cochran-Mantel-Haenszel test was performed to compare genotype combinations. Genotype distributions were in Hardy-Weinberg equilibrium (HWE) except for the Danish fertile group and the combined fertile group for FSHR 2039A>G (p = 0.002 and p = 0.0005). p < 0.05 was considered statistically significant. SPSS version 22 for Windows was used for all statistical analyses. The Danish and German groups of patients with TGCC were combined. Also, the two fertile groups were combined, as they did not differ in the distribution of genotypes (p > 0.05 in all three SNPs) ( Table S1 ). The Bonferroni correction for multiple testing was estimated 0.05/3 = 0.016.
Ethical approval
Approval was obtained from the Danish Regional Ethical Committee and the Danish Data Protection Agency (patients with TGCC, Datatilsynet 2012-41-1390, general population and fertile men H-KF-289428 and infertile men H-4-2010-138) and by the Ethics Committee of the Medical Faculty in M€ unster (Az 4|Nie). All participants, German and Danish, gave informed written consent. The study was conducted in accordance with the second Helsinki Declaration.
RESULTS
More patients with TGCC than fertile men had the A-allele of the FSHR 2039A>G (54.7% vs. 50.4%; p = 0.021, non-significant after Bonferroni correction for multiple testing, Table 1), with 30% of the AA-genotype compared to 22%, respectively (p = 0.002, significant after Bonferroni correction for multiple testing, Table 1 , Fig. 1A ) (combined, Denmark and Germany). This was reflected by an increased risk of testicular cancer in Aallele homozygotes with an odds ratio of 1.5 (95% CI: 1.2-1.9). Whereas the crude frequencies could indicate differences between patients with TGCC and infertile men or men from the general population, these differences were non-significant (Table 1) . The meta-analysis accounting for a potential heterogeneity of the cohorts from the two countries confirmed the results from the combined groups as it pointed to a significant overrepresentation of A-allele carriers among patients with TGCC (p = 0.02, OR 1.20 [95% CI: 1.03-1.39]).
The two promoter SNPs (FSHB -211G>T, FSHR -29G>A) did not differ in the distribution between the patients with TGCC and controls (Table 1) . However, the group of fertile men also had a significant lower frequency of the FSHR 2039 AA-genotype compared to both the infertile men (p = 0.038) and the general population (p = 0.001), while there was no significant difference in the allele frequency (p = 0.369 and p = 0.051, respectively). In combination with FSHR 2039A>G in a dominant model, both SNPs exhibited a tendency for higher frequency of wild-type combinations in TGCC compared to fertile men (Fig. 1B and C) . The combination of FSHR 2039A>G with FSHB -211G>T showed that 22% and 16% of the patients with TGCC and fertile controls, respectively, carried the combinations of homozygous wild-types (AA-GG). The combination of FSHR 2039A>G with FSHR -29G>A showed that 10% and 15% of the patients with TGCC and fertile controls, respectively, were homozygous for the wild-type alleles (AA-GG). However, chi-square test did not show any differences of the wild-type homozygous combinations or heterozygous combinations in patients with TGCC compared to fertile controls ( Fig. 1B and C) (FSHR -29G>A: p = 0.29 and p = 0.22, FSHB -211G>T, p = 1.0 and p = 0.5, respectively). In line with this, the Cochran-Mantel-Haenszel test did not demonstrate that the two promoter SNPs contribute further to the Figure 1 Comparison of genotypes of combined groups of fertile men and patients with TGCC. FSHR 2039A>G genotype distributions (A) and genotype combinations of FSHR -29G>A (B) and FSHB -211G>T (C) with FSHR 2039A>G, respectively. Blue and red circles represent combined groups of fertile men and patients with TGCC, respectively, including frequencies of genotype combinations. Chi-squared test p-value for comparison of fertile men and patients with TGCC according to FSHR 2039A>G genotypes is indicated (A, 2 9 3 cross- susceptibility to TGCC FSHR -29G>A: p = 0.50 and FSHB -211G>T p = 0.11). No differences in the genotype distribution (single SNPs or in combinations) between the seminomas and non-seminomas were detected (p > 0.05, data not shown), but the excess of wildtype homozygous FSHR 2039A>G was found in both the nonseminoma group (31.2%, p = 0.006) and the seminoma groups (29.4%, p = 0.011) compared to fertile men (22.0%). A sub-analysis without the patients exclusively affected by non-invasive GCNIS, and thus only on men with overt tumours, showed the same significant excess of the AA-genotype in the patients with TGCC compared to the fertile men (FSHR 2039A>G, p = 0.001).
Age at TGCC diagnosis was not associated to any of the three SNPs alone or in combination. In the Danish group, the 12.1% with bilateral neoplasia (either bilateral tumour or contralateral GCNIS) did not differ in genotype distributions of the three SNPs 
DISCUSSION
In this combined study of 752 Danish and German patients with testicular cancer, we observed that genetic variants associated with FSH activity may modulate the susceptibility to TGCC. Increased FSH receptor activity was associated with an increased risk of TGCC.
We detected a higher frequency of A-allele carrier of FSHR 2039A>G compared to fertile men. This might indicate that a higher FSH receptor activity could increase susceptibility for TGCC, and conversely -a less sensitive FSH receptor would decrease the susceptibility. Although we did not find a significant difference in genotype distribution of the two promoter SNPs, we detected a tendency of a high wild-type frequency, associated with higher FSH activity, in the patients with TGCC compared to the fertile men when combining genotypes. Our results are in partial accordance with an Italian study that also detected an increased frequency of the A-allele of FSHR 2039A>G in patients with TGCC (Ferlin et al., 2008) . While the previous study only observed a difference in the non-seminoma group, the observed difference in our group was evident in both seminomas and non-seminomas.
TGCC is believed to arise from germ cell neoplasia in situ (GCNIS) cells (Skakkebaek et al., 1987; Albers et al., 2011; Rajpert-De Meyts et al., 2015; Moch et al., 2016) , which are assumed to originate from foetal gonocytes that failed to develop into spermatogonia due to niche disturbances affecting the Sertoli cells (Rajpert-De Meyts et al., 2015) . Little is known about the role of FSH activity for early germ cell differentiation, but there is a clear sexual difference in the foetal FSH levels with considerably lower levels in the male foetus compared to female (Clements et al., 1976) and it has previously been suggested that GCNIS cells may be 'sexually confused' by the inadequately virilized somatic niche during testis development (Jørgensen & Rajpert-De Meyts, 2014) . FSH transiently increases during minipuberty, and there is some evidence that boys with cryptorchidism, a risk group for TGCC, have increased FSH levels already during this period (Suomi et al., 2006) . The pubertal increase in FSH acts synergistically with androgens on maturation of the Sertoli cells resulting in initiation and maintenance of spermatogenesis (Sharpe et al., 2003) . As activation of the hypothalamic-pituitary-gonadal axis in minipuberty and puberty seems to be necessary to drive the precursor cells into invasive cancer, we hypothesize that neoplastic transformation may depend on endocrine control. Late puberty has been reported to decrease the risk of TGCC (Maule et al., 2012) . Another indication that testicular activation by gonadotropins promotes development of TGCC is that only one TGCC case has been described in men with hypogonadotropic hypogonadism, despite this syndrome often is associated with cryptorchidism (Albers & Males, 1981) .
We cannot conclude whether increased FSH action augments susceptibility for perinatal persistence of foetal gonocytes resulting in GCNIS or if stronger FSHR activity facilitates invasive transformation of GCNIS into invasive cancer. If strong FSH action could result in earlier invasiveness, we would have expected to find association between genotypes and age of tumour development; however, this was not the case. Another possibility could be that the increased FSH action, presumably via a higher FSHR activity, results in better nursing function of Sertoli cells, hereby potentially protecting the GCNIS cells from apoptosis. Not fully differentiated Sertoli cells are often seen along with GCNIS cells and these could potentially be more responsive to FSH levels than the mature ones (Tarulli et al., 2013) .
Several studies reported the association between the three FSH-related genetic variants and testicular function through alteration of FSH action (Hoogendoorn et al., 2003; Desai et al., 2011; Casarini et al., 2014) . The minor alleles of each variant have been associated with reduced testicular function at different extent, but all with a background of reduced FSH action. One of the most common SNPs in the FSHR is non-synonymous SNP FSHR 2039A>G in exon 10 of the intracellular domain of the FSH receptor gene. In vitro studies of granulosa cells have demonstrated that the FSHR 2039 A>G genetic variants mediate different responses to FSH and that the homozygous A-allele exerts intracellular cAMP production faster than the homozygous Gallele . The possible association between this SNP and testicular function has been extensively investigated and some studies have detected association with higher FSH levels, lower testis volume as well as decreased Leydig cell function (Song et al., 2001; Zalata et al., 2008; Lindgren et al., 2012; T€ uttelmann et al., 2012; Grigorova et al., 2013) . Given the aetiology of TGCC and testicular function, we initially expected an underrepresentation of FSHR 2039 minor allele rather than the observed overrepresentation among TGCC cases. However, as previously shown the effect of the FSHR 2039 variant on bitesticular volume only becomes apparent in minor allele carriers of the FSHB variant pointing to a major effect of the FSHB variant on this outcome parameter (T€ uttelmann et al., 2012) . While FSHB genotype alone was not significantly associated with 180 Andrology, 2018, 6, 176-183 TGCC in our present study, we also tested for combinatory effects using the Cochran-Mantel-Haenszel test but did not observe any. Thus, we speculate that a higher FSH action mediated by FSHR 2039 may alter the TGCC risk rather than the sheer production of FSH which is altered by the FSHB variant.
In women, the G-allele has been demonstrated to be more frequent in ovulation disorders, infertility and associated with partial FSH resistance in ovarian stimulation (for overview (Simoni & Casarini, 2014) . It has been hypothesized that the fewer menstrual cycles associated with reduced FSH action could previously have had an evolutionary advantage resulting in a higher selection and distribution of this genotype (Simoni & Casarini, 2014) .
Recent genome-wide association studies (GWAS) identified at least 25 risk loci associated with TGCC, and the number has been growing with each study or meta-analysis Wang et al., 2017) . No loci in or around FSHR (chr2: 48, 841, 274, 775 GRCh38/hg38) have been identified among the risk loci, despite large numbers of patients and controls in meta-analytic studies. We speculate that this could be due to a complex polygenic character of the pathogenesis of TGCC and possible differences in distribution of significant polymorphisms among populations. The control groups used in GWAS represent a mixture of phenotypes, including infertile, fertile men and general population.
A strength of our study lies in using large groups of patients with TGCC and different control groups and the possibility to combine them. Our candidate gene approach minimizes the chance of false-positive findings. Highlighting the methodological difference compared to recent GWAS, we did not observe a significantly different genotype distribution in the general population but only in the fertile controls. Although we could replicate the results in the Danish fertile subgroup alone, we also detected the same tendencies, but non-significant, for the German fertile group, most probably due to the smaller numbers. Deviation from HWE of the fertile controls with an excess of heterozygous genotype of FSHR 2039A>G likely reflects selectivity of these groups rather than genotyping error as the same pattern was independently observed in both the Danish and the German fertile controls. However, we cannot rule out possible alternative explanations: the deviation of the fertile control group from HWE may be explained by an artificial underrepresentation of the A-allele in the fertile control group.
The study is not free of limitations, mainly concerning potential selection bias. It is possible that patients with TGCC recruited via andrology centres, which was the case in this study, may differ from other cohorts, for example because of more severe testicular failure and a prolonged exposure to high gonadotropin levels. Further, as multiple testing was conducted, we applied Bonferroni correction for multiple testing. While the Chi-squared test for allele frequencies lost significance after Bonferroni correction for multiple testing, the Chi-squared test for genotype frequencies remained significant.
Our observations concerning a significant difference between TGCC vs. fertile controls are based on the rationale that these groups are on 'opposite sides' of the spectrum of testicular function. This means that patients with TGCC represent the group with the poorest testicular development, with a better situation in infertile men in general followed by the men from the general population (where some will later show up to be infertile and some will develop TGCC) to fertile men having the best-developed testicles. A reduced risk of testicular cancer has been associated with paternity and -conversely -male subfertility with increased risk of GCNIS testicular cancer (Møller & Skakkebaek, 1999; Olesen et al., 2007) . However, we did not observe a significant difference in genotype frequencies between infertile men and men from the general population compared to patients with TGCC. It is plausible that men in the three control groups and especially the relatively young men from the general populations and the infertile men may develop TGCC later in life. This bias will tend to diminish the differences between these groups and the patients with TGCC.
In conclusion, we observed a higher frequency of A-allele carriers of FSHR 2039A>G among patients with TGCC compared to fertile men. As this allele is associated with an increased FSH action, our results strengthen the evidence that FSH signalling may be involved in modulation of the risk of TGCC.
